The decision reverses an administrative judge’s ruling that dismissed the FTC’s initial challenge of Illumina’s $7.1 billion Grail deal.

Illumina told shareholders that Carl Icahn’s board nominees would “threaten the progress” of the biotech company’s core business.

Carl Icahn claims Illumina directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of Grail